Healius (ASX:HLS) reported Thursday that its underlying loss per diluted share in the fiscal first half narrowed to AU$0.0279, from a loss of AU$0.031 per diluted share a year earlier.
Analysts polled by FactSet were expecting a loss of AU$0.01 per share.
Revenue for the six months ended Dec. 31, 2024, was AU$662.3 million, up from AU$620.8 million in the same period a year earlier. Analysts surveyed by FactSet expected sales of AU$913 million.
The healthcare company expects fiscal 2025 earnings before interest and taxes from Agilex Biolabs to be similar to last year's AU$5.1 million.
The company's shares were down past 4% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。